CIMPLRX

Cimplrx is a South Korean drug discovery company leveraging its proprietary, explainable artificial intelligence (XAI)-guided platform, CEEK-CURE, to discover and optimize novel small-molecule therapeutics. Founded in 2017 by Dr. Sung Jin Cho, the company integrates computational tools with structured experimental datasets to make drug discovery workflows more traceable, transparent, and chemistry-aware. Cimplrx operates a hybrid business model, advancing an in-house pipeline focused on neuropathic pain while collaborating with major pharmaceutical partners across oncology, central nervous system (CNS) diseases, autoimmune disorders, and metabolic conditions. Its lead internal program is a potent and selective small-molecule inhibitor of Adaptor-related protein complex 2-associated kinase 1 (AAK1) for the treatment of neuropathic pain, currently in late-stage lead optimization.